202 related articles for article (PubMed ID: 35220238)
21. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
22. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
Mehta R; Shah G; Adler W; Kittur D
Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
[TBL] [Abstract][Full Text] [Related]
23. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer.
Ostenstad B
Acta Oncol; 1992; 31(4):413-5. PubMed ID: 1632975
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma.
Choudhary MM; Gupta A; Bena J; Emch T; Singh AD
JAMA Ophthalmol; 2016 Feb; 134(2):174-80. PubMed ID: 26633182
[TBL] [Abstract][Full Text] [Related]
25. Latest developments in the biology and management of uveal melanoma.
Patel SP
Curr Oncol Rep; 2013 Dec; 15(6):509-16. PubMed ID: 24122445
[No Abstract] [Full Text] [Related]
26. Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases.
Barnhill R; Vermeulen P; Daelemans S; van Dam PJ; Roman-Roman S; Servois V; Hurbain I; Gardrat S; Raposa G; Nicolas A; Dendale R; Pierron G; Desjardins L; Cassoux N; Piperno-Neumann S; Mariani P; Lugassy C
J Pathol Clin Res; 2018 Oct; 4(4):227-240. PubMed ID: 29917326
[TBL] [Abstract][Full Text] [Related]
27. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
28. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
29. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
30. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
31. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
34. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein.
Izzo F; Cremona F; Delrio P; Leonardi E; Castello G; Pignata S; Daniele B; Curley SA
Ann Surg Oncol; 1999 Mar; 6(2):178-85. PubMed ID: 10082044
[TBL] [Abstract][Full Text] [Related]
35. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.
Ragusa M; Barbagallo C; Statello L; Caltabiano R; Russo A; Puzzo L; Avitabile T; Longo A; Toro MD; Barbagallo D; Valadi H; Di Pietro C; Purrello M; Reibaldi M
Cancer Biol Ther; 2015; 16(9):1387-96. PubMed ID: 25951497
[TBL] [Abstract][Full Text] [Related]
36. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
37. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S; Balian A; Degos F; Daurat V; Chevret S; Gayno S; Bastie A; Riachi G; Bartolomei-Portal I; Barange K; Moussalli J; Bailly F; Chaumet-Riffaud P; Emilie D
J Hepatol; 1999 Oct; 31(4):612-7. PubMed ID: 10551383
[TBL] [Abstract][Full Text] [Related]
39. Liver function tests in metastatic uveal melanoma.
Kaiserman I; Amer R; Pe'er J
Am J Ophthalmol; 2004 Feb; 137(2):236-43. PubMed ID: 14962411
[TBL] [Abstract][Full Text] [Related]
40. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
